Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9776648 | 0.87 | GABRA1 (0.72) | GABRA1GABRB2POLBGAAMAPT | |
| SCHEMBL9447458 | 0.82 | GABRA1 (0.38) | GABRA1GABRB2POLBGAAMAPT | |
| SCHEMBL51567 | 0.79 | HIF1A (0.48) | MAPTKMT2AMEN1HPGDLMNA | |
| SCHEMBL7651615 | 0.77 | LOXL2 (0.41) | GABRA1GABRB2 | |
| SCHEMBL6214320 | 0.77 | KLF10 (0.46) | KMT2AMEN1CA12CA2CA3 | |
| SCHEMBL587985 | 0.76 | KDM4C (0.33) | GABRA1GABRB2CA12CA2CA3 | |
| SCHEMBL25054203 | 0.76 | LOXL2 (0.47) | CA12CA2CA3CA6CA9 | |
| SCHEMBL12594178 | 0.76 | AR (0.54) | CA12CA2CA3CA6CA9 | |
| SCHEMBL1741193 | 0.75 | CYP2A6 (0.38) | GABRA1GABRB2POLBGAAMAPT | |
| SCHEMBL252293 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3031248-A | — | — | None | — | — | JP | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| WO-1996004905-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| EP-0654032-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS. | ZENECA LTD (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| JP-H0331248-A | ETHER DERIVATIVE OF CYANOALLYLPHENOL | CHISSO CORP | 1991-02-12 | — | — | JP | disclosed |
| EP-0193853-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4783462-A | 3(2H)pyridazinone, and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0193853-A2 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | VIP, TMPRSS15, MMP2 | GABRA1 4350/4885GABRB2 3493/4885POLB 4151/4885 |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | GABRA1 204/4885GABRB2 239/4885POLB 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.